Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan
Tolvaptan treatment is costly, often accompanied by aquaresis-related adverse events, and requires careful monitoring by medical staff due to the possibility of hepatotoxicity. Nevertheless, it is the only disease-modifying drug to date that has been shown to successfully delay renal replacement the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kosin University College of Medicine
2023-06-01
|
| Series: | Kosin Medical Journal |
| Subjects: | |
| Online Access: | http://www.kosinmedj.org/upload/pdf/kmj-23-125.pdf |
| _version_ | 1797792536613355520 |
|---|---|
| author | Yeonsoon Jung Yun Kyu Oh |
| author_facet | Yeonsoon Jung Yun Kyu Oh |
| author_sort | Yeonsoon Jung |
| collection | DOAJ |
| description | Tolvaptan treatment is costly, often accompanied by aquaresis-related adverse events, and requires careful monitoring by medical staff due to the possibility of hepatotoxicity. Nevertheless, it is the only disease-modifying drug to date that has been shown to successfully delay renal replacement therapy. For more patients to receive proper treatment, medical doctors, the rest of the medical team, and the patient must all work together. This paper reviews parameters that can help identify rapid autosomal dominant polycystic kidney disease progressors, who are the target of tolvaptan therapy. It is expected that these parameters will help nephrologists learn practical prescription methods and identify patients who can benefit from tolvaptan treatment. Although several strategies can be used to find rapid progressors, the present review focuses on a practical method to identify rapid progressors according to the presence or absence of evidence and the factors associated with rapid progression based on the Mayo image classification. |
| first_indexed | 2024-03-13T02:34:25Z |
| format | Article |
| id | doaj.art-96ce37d0c8ab4749800b249c418f53c0 |
| institution | Directory Open Access Journal |
| issn | 2005-9531 2586-7024 |
| language | English |
| last_indexed | 2024-03-13T02:34:25Z |
| publishDate | 2023-06-01 |
| publisher | Kosin University College of Medicine |
| record_format | Article |
| series | Kosin Medical Journal |
| spelling | doaj.art-96ce37d0c8ab4749800b249c418f53c02023-06-29T08:07:28ZengKosin University College of MedicineKosin Medical Journal2005-95312586-70242023-06-01382879710.7180/kmj.23.1251242Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptanYeonsoon Jung0Yun Kyu Oh1 Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, KoreaTolvaptan treatment is costly, often accompanied by aquaresis-related adverse events, and requires careful monitoring by medical staff due to the possibility of hepatotoxicity. Nevertheless, it is the only disease-modifying drug to date that has been shown to successfully delay renal replacement therapy. For more patients to receive proper treatment, medical doctors, the rest of the medical team, and the patient must all work together. This paper reviews parameters that can help identify rapid autosomal dominant polycystic kidney disease progressors, who are the target of tolvaptan therapy. It is expected that these parameters will help nephrologists learn practical prescription methods and identify patients who can benefit from tolvaptan treatment. Although several strategies can be used to find rapid progressors, the present review focuses on a practical method to identify rapid progressors according to the presence or absence of evidence and the factors associated with rapid progression based on the Mayo image classification.http://www.kosinmedj.org/upload/pdf/kmj-23-125.pdfpatient selectionpolycystic kidney, autosomal dominanttolvaptan |
| spellingShingle | Yeonsoon Jung Yun Kyu Oh Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan Kosin Medical Journal patient selection polycystic kidney, autosomal dominant tolvaptan |
| title | Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan |
| title_full | Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan |
| title_fullStr | Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan |
| title_full_unstemmed | Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan |
| title_short | Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan |
| title_sort | are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey real practice for selecting rapid progressors and treatment with tolvaptan |
| topic | patient selection polycystic kidney, autosomal dominant tolvaptan |
| url | http://www.kosinmedj.org/upload/pdf/kmj-23-125.pdf |
| work_keys_str_mv | AT yeonsoonjung areyoureadytoaccompanyautosomaldominantpolycystickidneydiseasepatientsintheirtreatmentjourneyrealpracticeforselectingrapidprogressorsandtreatmentwithtolvaptan AT yunkyuoh areyoureadytoaccompanyautosomaldominantpolycystickidneydiseasepatientsintheirtreatmentjourneyrealpracticeforselectingrapidprogressorsandtreatmentwithtolvaptan |